Search Results - "Burris III, Howard"

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies by Johnson, Melissa L, Patel, Manish R, Aljumaily, Raid, Jones, Suzanne F, Burris, III, Howard A, Spigel, David R

“…Abstract Background This was an open-label, multicenter, single-arm phase Ib dose-escalation study of oral LCL161 administered in combination with oral…”
Get full text

Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute by Yardley, Denise A., Bosserman, Linda D., O’Shaughnessy, Joyce A., Harwin, William N., Morgan, Susan K., Priego, Victor M., Peacock, Nancy W., Bass, J. David, Burris III, Howard A., Hainsworth, John D.

“…Amplified PI3K/Akt/mTOR signaling is common in metastatic breast cancer (MBC). The mTOR inhibitor everolimus improves progression-free survival (PFS) when…”
Get full text

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer by Girish, Sandhya, Gupta, Manish, Wang, Bei, Lu, Dan, Krop, Ian E., Vogel, Charles L., Burris III, Howard A., LoRusso, Patricia M., Yi, Joo-Hee, Saad, Ola, Tong, Barbara, Chu, Yu-Waye, Holden, Scott, Joshi, Amita

“…Purpose Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate comprising trastuzumab and DM1, a microtubule polymerization inhibitor, covalently bound…”
Get full text

New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways by Burris, Howard, Rocha‐Lima, Caio

“…Learning Objectives After completing this course, the reader will be able to: Evaluate the existing chemotherapeutic options for advanced pancreatic cancer…”
Get full text

Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors by Infante, Jeffrey R., Keedy, Vicki L., Jones, Suzanne F., Zamboni, William C., Chan, Emily, Bendell, Johanna C., Lee, Wooin, Wu, Huali, Ikeda, Satoshi, Kodaira, Hiroshi, Rothenberg, Mace L., Burris III, Howard A.

“…Purpose IHL-305 is a novel PEGylated liposome containing irinotecan. This study examined the safety profile and pharmacokinetics of IHL-305 and established the…”
Get full text

pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer by Yardley, Denise, Burris, Howard III, Peacock, Nancy, Raefsky, Eric, Melnik, Marianne, Inhorn, Roger, Shipley, Dianna, Hainsworth, John

“…nab-Paclitaxel has shown favorable efficacy and toxicity profiles compared to other taxanes in the treatment of metastatic breast cancer. In this pilot trial,…”
Get full text

Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial by Infante, Jeffrey, Arkenau, Hendrik-Tobias, Bendell, Johanna, Rubin, Mark, Waterhouse, David, Jones, George, Spigel, David, Lane, Cassie, Hainsworth, John, Burris, III, Howard

“…Objectives: To evaluate the 6-mo overall survival, safety and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for…”
Get full text

Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer by Lu, Dan, Burris, 3rd, Howard A, Wang, Bei, Dees, E Claire, Cortes, Javier, Joshi, Amita, Gupta, Manish, Yi, Joo-Hee, Chu, Yu-Waye, Shih, Ted, Fang, Liang, Girish, Sandhya

“…Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate comprised of trastuzumab and the cytotoxic agent DM1 (derivative of maytansine) linked by a stable…”
Get more information

A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine by Infante, Jeffrey R., Jones, Suzanne F., Bendell, Johanna C., Greco, F. Anthony, Yardley, Denise A., Lane, Cassie M., Spigel, David R., Hainsworth, John D., Burris III, Howard A.

“…Purpose To address tolerability and a possible pharmacologic interaction of capecitabine with sorafenib. Methods Patients with advanced solid tumors (ECOG PS…”
Get full text

Revolutionizing cancer drug development: Harnessing the potential of basket trials by Subbiah, Vivek, Burris, Howard A., Kurzrock, Razelle

“…The landscape of cancer therapy has been transformed by advances in clinical next‐generation sequencing, genomically targeted therapies, and immunotherapies…”
Get full text

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial by Qin, Shukui, Chen, Minshan, Kudo, Masatoshi, Yopp, Adam C, Wang, Lu, Tak, Won Young, Lian, Qinshu, Spahn, Jessica H, Wang, Yulei, Chow, Pierce K H, Poursoltan, Pirooz, Kiberu, Andrew, Chittajallu, Renuka, Sood, Siddarth, Stauber, Rudolf, Peck-Radosavljevic, Markus, Decaestecker, Jochen, Verset, Gontran, Cunha Júnior, Ademar, Faria, Luiza, Asselah, Jamil, Brahmania, Mayur, Li, Qiang, Chen, Zhendong, Zhao, Haitao, Liu, Hongming, Wu, Feixiang, Zheng, Qichang, Li, Haitao, Wen, Tianfu, Qin, Shukui, Liu, Yunpeng, Chen, Minshan, Bai, Yuxian, Zhao, Hong, Yin, Tao, Ding, Youming, Jia, Weidong, Xia, Yongxiang, Xia, Qiang, Guzmán, Adrián, Corrales, Luis, Kubala, Eugen, Blanc, Jean Frederic, Borg, Christophe, Decaens, Thomas, Uguen, Thomas, Heurgue, Alexandra, Trojan, Joerg, Gonzalez-Carmona, Maria Angeles, Schotten, Clemens, Kandulski, Arne, Yau, Thomas, Scartozzi, Mario, Leonardi, Francesco, Ghidini, Michele, Kudo, Masatoshi, Koga, Hironori, Kawamura, Yusuke, Hasegawa, Kiyoshi, Marusawa, Hiroyuki, Hayashi, Hiromitsu, Lee, Han Chu, Paik, Seung Woon, Kim, Do Young, Jeong, Sook-Hyang, Kim, Hyeyeong, Yoon, Seung Kew, Yoon, Jung-Hwan, Villalobos, Ricardo, Martinez Rodriguez, Jorge Luis, Oyervides Juarez, Victor, Hernández, Carlos Alberto, de Vos-Geelen, Judith, Gane, Edward, Torres Mattos, Cesar, Alyasova, Anna, Sekacheva, Marina, Ledin, Evgeny, Toh, Han Chong, Lopez Lopez, Carlos, Muñoz Martin, Andres Jesus, Reig Monzón, Maria, Delgado Mingorance, Ignacio, Minguez Rosique, Beatriz, Huang, Yi-Hsiang, Huang, Jee-Fu, Su, Wei-Wen, Maneenil, Kunlatida, Harputluoglu, Hakan, Buchschacher, Gary, Xiong, Henry, Patel, Mital, Li, Daneng, Brooks, Gabriel, Patel, Reema, Kardosh, Adel, Shah, Ashesh, Burris III, Howard, Hsiehchen, David

“…No adjuvant treatment has been established for patients who remain at high risk for hepatocellular carcinoma recurrence after curative-intent resection or…”
Get full text

Variable detection of actionable alterations across racial groups and association with testing patterns by Sturgill, Emma, Correia, Jessica, Schumacher, Cooper, Luckett, Daniel, Jones, Suzanne Fields, Burris III, Howard A., Spigel, David R., McKenzie, Andrew Jacob

“…3116 Background: Molecular landscape studies are critical to biomarker discovery and precision oncology research. However, non-White patients (pts) have…”
Get full text

Concordance of blood and tissue TMB from NGS testing in real-world settings and their ability to predict response to immunotherapy by Sturgill, Emma, Misch, Amanda, Jones, Carissa, Luckett, Daniel, Fu, Xiaotong, Jones, Suzanne Fields, Burris III, Howard A., Spigel, David R., McKenzie, Andrew Jacob

“…Abstract only 2540 Background: Tumor mutational burden (TMB) detected by tissue-based Next Generation Sequencing (NGS) is a biomarker for immunotherapy (IO)…”
Get full text

A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors by Lakhani, Nehal J, Burris, 3rd, Howard, Miller, Jr, Wilson H, Huang, Mo, Chen, Lin-Chi, Siu, Lillian L

“…Combining a checkpoint inhibitor with an inhibitor of extracellular signal-regulated kinase (ERK) may result in synergistic antitumor activity. We evaluated…”
Get full text

Real-world data evaluating immunotherapy markers and checkpoint inhibitor response among GI cancers in a large community-based oncology network by Jones, Carissa, Lachs, Rebecca, Sturgill, Emma, Misch, Amanda, Lietman, Caressa, Jones, Suzanne Fields, Burris III, Howard A., Sen, Shiraj, Bendell, Johanna C.

“…Abstract only 113 Background: Checkpoint inhibitor (CPI) therapies have shown prolonged survival in patients (pts) with microsatellite instability (MSI). Tumor…”
Get full text

Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer by Burris III, Howard A., Okusaka, Takuji, Vogel, Arndt, Lee, Myung Ah, Takahashi, Hidenori, Breder, Valeriy Vladimirovich, Blanc, Jean-Frédéric, Li, Junhe, Watras, Magdalena, Xiong, Julia, Abraham, Jayne, Patel, Nikunj, Wang, Julie, Rokutanda, Nana, Cohen, Gordon, Oh, Do-Youn

“…4070 Background: TOPAZ-1 (NCT03875235) is a randomized, double-blind, global, Phase 3 study evaluating the efficacy and safety of durvalumab (D) in combination…”
Get full text

Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA) by Elimova, Elena, Ajani, Jaffer A., Burris III, Howard A., Denlinger, Crystal S., Iqbal, Syma, Kang, Yoon-Koo, Kim, YEUL HONG Hong, Lee, Keun-Wook, Lin, Bruce, Mehta, Rutika, Oh, Do-Youn, Rha, Sun Young, Soel, Yong Mi, Boyken, Lisa, Grim, Jonathan E., Ku, Geoffrey Yuyat

“…347 Background: Zanidatamab (zani) is an anti-HER2 bispecific antibody against ECD4 and ECD2 with demonstrated activity and tolerability in a range of…”
Get full text

Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer by Bouattour, Mohamed, Valle, Juan W., Vogel, Arndt, Kim, Jin Won, Kitano, Masayuki, Chen, Jen-Shi, Burris III, Howard A., Zaucha, Renata, Qin, Shukui, Evesque, Ludovic, Zhen, David Bing, Gupta, Vineet Govinda, Park, Joon Oh, Żotkiewicz, Magdalena, Rokutanda, Nana, Cohen, Gordon, Oh, Do-Youn

“…531 Background: At the primary analysis of TOPAZ-1 (NCT03875235; data cut-off [DCO] Aug 11, 2021), durvalumab (D) + gemcitabine and cisplatin (GC)…”
Get full text

Clinical and molecular presentation of KRAS G12D-mutated pancreatic ductal adenocarcinoma in real-world settings by Sturgill, Emma G., Kolli, Sahiti, Feustel, Kavanya, Luckett, Daniel, Jones, Carissa, Holt, Marilyn Elaine, Hyde, Annastasia, Jones, Suzanne Fields, Perez, Cesar Augusto, Wang, Judy S., Divers, Stephen G., Pelster, Meredith, Henry, Jason Timothy, Spigel, David R., Burris III, Howard A., McKenzie, Andrew Jacob

“…738 Background: Pancreatic ductal adenocarcinoma (PDAC) remains a devastating diagnosis with an overall 5-year survival rate of ~10%. Therapies targeting KRAS…”
Get full text

MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors by Meric-Bernstam, Funda, Hainsworth, John, Bose, Ron, Burris III, Howard A., Friedman, Claire Frances, Kurzrock, Razelle, Swanton, Charles, Wang, Yong, Levy, Jonathan, Schulze, Katja, Price, Richard, Patel, Arisha, Sweeney, Christopher

“…Abstract only 3004 Background: HER2 ( ERBB2) amplification and/or overexpression is observed in 2–3% of solid tumors, and is often associated with more…”
Get full text